Article
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet (London, England) - 16 Jul 2011
Molina Jean-Michel, Cahn Pedro, Grinsztejn Beatriz, Lazzarin Adriano, Mills Anthony, Saag Michael, Supparatpinyo Khuanchai, Walmsley Sharon, Crauwels Herta, Rimsky Laurence T, Vanveggel Simon, Boven Katia
Abstract excerpt
BACKGROUND: Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to efavirenz in a phase 2b trial with two nucleoside/nucleotide reverse transcriptase inhibitors. We aimed to assess the efficacy, safety, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.